Literature DB >> 9367795

Phenotypic comparison of an osteogenesis imperfecta type IV proband with a de novo alpha2(I) Gly922 --> Ser substitution in type I collagen and an unrelated patient with an identical mutation.

A Forlino1, E D'amato, M Valli, G Camera, E Hopkins, J C Marini, G Cetta, D A Coviello.   

Abstract

We examined the type I collagen synthesized by cultured dermal fibroblasts from a patient affected with osteogenesis imperfecta (OI) type IV. Both normal and abnormal trimers were produced. The mutant collagen molecules were excessively modified intracellularly, had a melting temperature 4 degrees C lower than the control, were secreted at a reduced rate, and underwent delayed processing to mature alpha chains.Molecular investigations identified a G --> A transition in one COL1A2 allele, resulting in a Gly922 --> Ser substitution in the alpha2(I) chain. The proband's mutation was demonstrated to arise "de novo" by the absence of the mutant allele restriction enzyme pattern from parental genomic DNA.We analyzed the insoluble extracellular matrix deposited by long-term cultured fibroblasts from our patient and from a previously described unrelated individual who carries an identical substitution. In both cases, the mutant chain constituted 10-15% of the total alpha chains deposited.We also present here the first detailed comparison of phenotype between unrelated OI patients with an identical collagen mutation. These two patients are both Caucasian females, ages 8 and 9 years, each diagnosed as type IV OI by the Sillence classification. They have a similar phenotype including moderate skeletal fragility with several femur fractures, dentinogenesis imperfecta, wormian bone, and reduced height and weight. We conclude that this phenotype is related both to the location of this mutation and to the similar extent of matrix incorporation by the mutant chains. Molecular and biochemical studies of unrelated individuals with identical amino acid substitutions in type I collagen resulting in either similar or dissimilar clinical outcomes will make a significant contribution to identifying the factors involved in the modulation of the OI phenotype. Copyright 1997 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9367795     DOI: 10.1006/bmme.1997.2620

Source DB:  PubMed          Journal:  Biochem Mol Med        ISSN: 1077-3150


  7 in total

1.  Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta.

Authors:  Wayne A Cabral; Weizhong Chang; Aileen M Barnes; MaryAnn Weis; Melissa A Scott; Sergey Leikin; Elena Makareeva; Natalia V Kuznetsova; Kenneth N Rosenbaum; Cynthia J Tifft; Dorothy I Bulas; Chahira Kozma; Peter A Smith; David R Eyre; Joan C Marini
Journal:  Nat Genet       Date:  2007-02-04       Impact factor: 38.330

2.  Absence of FKBP10 in recessive type XI osteogenesis imperfecta leads to diminished collagen cross-linking and reduced collagen deposition in extracellular matrix.

Authors:  Aileen M Barnes; Wayne A Cabral; MaryAnn Weis; Elena Makareeva; Edward L Mertz; Sergey Leikin; David Eyre; Carlos Trujillo; Joan C Marini
Journal:  Hum Mutat       Date:  2012-07-16       Impact factor: 4.878

3.  Genetic Defects in TAPT1 Disrupt Ciliogenesis and Cause a Complex Lethal Osteochondrodysplasia.

Authors:  Sofie Symoens; Aileen M Barnes; Charlotte Gistelinck; Fransiska Malfait; Brecht Guillemyn; Wouter Steyaert; Delfien Syx; Sanne D'hondt; Martine Biervliet; Julie De Backer; Eckhard P Witten; Sergey Leikin; Elena Makareeva; Gabriele Gillessen-Kaesbach; Ann Huysseune; Kris Vleminckx; Andy Willaert; Anne De Paepe; Joan C Marini; Paul J Coucke
Journal:  Am J Hum Genet       Date:  2015-09-10       Impact factor: 11.025

4.  Substitution of murine type I collagen A1 3-hydroxylation site alters matrix structure but does not recapitulate osteogenesis imperfecta bone dysplasia.

Authors:  Wayne A Cabral; Nadja Fratzl-Zelman; MaryAnn Weis; Joseph E Perosky; Adrienne Alimasa; Rachel Harris; Heeseog Kang; Elena Makareeva; Aileen M Barnes; Paul Roschger; Sergey Leikin; Klaus Klaushofer; Antonella Forlino; Peter S Backlund; David R Eyre; Kenneth M Kozloff; Joan C Marini
Journal:  Matrix Biol       Date:  2020-02-26       Impact factor: 11.583

5.  Abnormal type I collagen post-translational modification and crosslinking in a cyclophilin B KO mouse model of recessive osteogenesis imperfecta.

Authors:  Wayne A Cabral; Irina Perdivara; MaryAnn Weis; Masahiko Terajima; Angela R Blissett; Weizhong Chang; Joseph E Perosky; Elena N Makareeva; Edward L Mertz; Sergey Leikin; Kenneth B Tomer; Kenneth M Kozloff; David R Eyre; Mitsuo Yamauchi; Joan C Marini
Journal:  PLoS Genet       Date:  2014-06-26       Impact factor: 5.917

6.  Absence of the ER Cation Channel TMEM38B/TRIC-B Disrupts Intracellular Calcium Homeostasis and Dysregulates Collagen Synthesis in Recessive Osteogenesis Imperfecta.

Authors:  Wayne A Cabral; Masaki Ishikawa; Matthias Garten; Elena N Makareeva; Brandi M Sargent; MaryAnn Weis; Aileen M Barnes; Emma A Webb; Nicholas J Shaw; Leena Ala-Kokko; Felicitas L Lacbawan; Wolfgang Högler; Sergey Leikin; Paul S Blank; Joshua Zimmerberg; David R Eyre; Yoshihiko Yamada; Joan C Marini
Journal:  PLoS Genet       Date:  2016-07-21       Impact factor: 5.917

7.  Osteogenesis Imperfecta: Search for Mutations in Patients from the Republic of Bashkortostan (Russia).

Authors:  Dina Nadyrshina; Aliya Zaripova; Anton Tyurin; Ildar Minniakhmetov; Ekaterina Zakharova; Rita Khusainova
Journal:  Genes (Basel)       Date:  2022-01-10       Impact factor: 4.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.